
Dennis J. Slamon, MD, PhD, discusses the use of nonanthracycline-based regimens to treat patients with early breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss clinical trial results supporting the use of nonanthracycline-containing regimens for treating early breast cancer patients
- Describe the role of topoisomerase II alpha in determining HER2 sensitivity to anthracyclines in early breast cancer
- Explain the implication of HER2 status in determining the best treatment option for early breast cancer patients